Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 1,401–1,500 of 2,053
Kommentar zu „Typ-2-Diabetes: SGLT2-Inhibitoren und DPP4-Inhibitoren im Vergleich“
Menzen, M. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2058-1588
Hatulely, C. A. (2023) · Journal of Advance Research in Medical & Health Science · doi:10.53555/nnmhs.v9i8.1810 · Cited by 3
Primary Care Medicine - Theory and Practice
Çakmur, H. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.111122 · Cited by 1
Einfluss von körperlichem Training auf die Betazellfunktion bei Typ-2-Diabetes
Bokeloh, T., & Schlögl, H. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01084-7
Andersen, J. A., Felix, H. C., Malhis, J. R., Gloster, E., & McElfish, P. A. (2023) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.1177/11795514231183595 · Cited by 1
RODRIGUES, L. M. D. F., FILHO, T. F. D. S., ALMEIDA, F. D. O., et al. (2023) · doi:10.58871/ed.academic21062023.22
EFICÁCIA E SEGURANÇA DE NOVAS ABORDAGENS FARMACOLÓGICAS NO TRATAMENTO DA DIABETES TIPO 2
Pereira, A. C. S., Torres, L. M. C., Biasi, M. P., Scartazzini, M. V. S., Figueiredo, L. M., Côrtes, P. H., Ramos, R. C., da Silva, T. H., Brandão, P. A. D. V., & Cavalcante, I. F. D. M. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i7.10786
Alanazi, F. K., Almofarh, A. A., Alzahrani, I. A., AlFahid, F. A., alhamdi, M. H., Alfaifi, M. G. Y., Alanazi, F. R. R., khaledalshehri, A., & Alharbi, H. A. (2023) · International Journal of Engineering Applied Sciences and Technology · doi:10.33564/ijeast.2023.v08i03.006 · Cited by 1
Tahrani, A. A. (2023) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2023.09.007
Ferdous, K., Rahman, M. A., Islam, S., Tasnim, S., Rahaman, S., Islam, M. R., Hossain, M. B., & Tasnim, S. (2023) · American Journal of Life Science and Innovation · doi:10.54536/ajlsi.v2i3.1928
ปิยสาธิต, ป., & สนับบุญ, ธ. (2019) · Chula Digiverse · doi:10.58837/chula.the.2019.1488
Mohapatra, A. K., Deo, B., & Alramadan, A. (2023) · Cardiology and Vascular Medicine · doi:10.33425/2768-0436.1016
Heald, A. H., Warner-Levy, J. J., Belston, L., Habte‐Asres, H. H., Horne, L., Metters, A., Whyte, M., & Gibson, M. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000293
Murayama, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3396067/v1
Penyuluhan Aktifitas Fisik dalam Mencegah Penyakit Diabetes Melitus pada Remaja
Syaripudin, A., & Purbasari, D. (2023) · JURNAL KREATIVITAS PENGABDIAN KEPADA MASYARAKAT (PKM) · doi:10.33024/jkpm.v6i10.11479
Orioli, L., Servais, T., Crenier, L., et al. (2023) · Annales d Endocrinologie · doi:10.1016/j.ando.2023.10.001
Cybersecurity in the Western Balkans and European Regulation
Bajraktari, H., & Qatani, V. (2023) · West Science Law and Human Rights · doi:10.58812/wslhr.v1i04.313
Promoting kidney health in people with type 2 diabetes: part 2
Murphy, F. L. M., & Byrne, G. (2023) · British Journal of Nursing · doi:10.12968/bjon.2023.32.20.964
“…a management plan, jointly agree on modifications, confirm agreed changes of treatment are instigated in a timely manner to avert therapeutic inactivity, assess decision cycle routinely (at a minimum of once or twice per year) and function in an integrated scheme of care (Davies et al, 2018; 2022).”
BackgroundInfluentialVeryanti, P. R., Sartika, R. A. D., Sauriasari, R., Elya, B., & Puspitasari, R. M. (2023) · JURNAL ILMU KEFARMASIAN INDONESIA · doi:10.35814/jifi.v21i2.1477
Jashi, L., Peshkova, T., & Kvanchakhadze, R. (2023) · International Journal of Medical Science and Health Research · doi:10.51505/ijmshr.2023.7508
Ніколаєнко-Камишова, Т., & Височина, І. (2023) · Перспективи та інновації науки · doi:10.52058/2786-4952-2023-15(33)-1232-1239
Mokoagow, M. I. (2023) · Cermin Dunia Kedokteran · doi:10.55175/cdk.v50i12.1014
Diabetes mellitus in acromegaly: prevalence, pathophysiological particulars and treatment strategies
Ilovayskaya, I., & Galstyan, G. R. (2023) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2023-51-037
Novedades en los Standards of Care in Diabetes 2023
Hernández, C. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.1.art1
Rådholm, K., af Geijerstam, P., Woodward, M., Chalmers, J. P., Hellgren, M. I., Jansson, S. P. O., & Rolandsson, O. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1265645
Lautenbach, A., Wiesch, C. S. Z., & Aberle, J. (2023) · Aktuelle Ernährungsmedizin · doi:10.1055/a-2185-5427
“Unter Berücksichtigung der drei prioritären Behandlungsziele (Blutzuckerkontrolle, Kardio- und Nephroprotektion sowie Gewichtsreduktion) wird im aktuellen Konsensus Report Metformin nicht mehr explizit als alleinige Erstlinientherapie empfohlen, da GLP-1 Rezeptor-Agonisten (RA) und SGLT2-Inhibitoren aufgrund ihrer gün…”
BackgroundERYTHROPOIETIN SYNTESIS IN PATIENTS WITH CHRONIC HEART FAILURE DEPENDING ON COMORBID PATHOLOGY
Pavliukovych, N. D., ГУСАК, В., Pavliukovych, O., et al. (2023) · Clinical and Preventive Medicine · doi:10.31612/2616-4868.7.2023.05
Prognostic Value of Fibrinogen-to-Albumin Ratio in Coronary Three-Vessel Disease [Letter]
Guo, Y., & Nong, Y. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s455664
Salinas, M. E. M. (2023) · Universidad Privada San Juan Bautista · doi:10.59590/upsjb/fcs.med.hum/tesis/4455
Scientific Exercises and Right Diet-The Consummate Combination for an Incontrovertible Metabolism
Balachandar, J. C., Ahamed, S. I., & Jayachandran, M. (2023) · Endocrine System and Diabetes · doi:10.58489/2836-502x/008
El-Naggar, S. A., Salama, W. M., El-Desouki, N. I., Tabl, G. A., Jobier, R. A., & Abdelsattar, A. (2023) · Journal of Bioscience and Applied Research/Journal of Bioscience and Applied Research · doi:10.21608/jbaar.2023.333006
SGLT2 Inhibitors and Perioperative Euglycemic Diabetic Ketoacidosis
Mrazek, A. A. (2023) · Anaesthesia & Critical Care Medicine Journal · doi:10.23880/accmj-16000231
The Many Faces and Facets of Dysglycemia
HEILE, M. K. (2024) · Clinical Diabetes · doi:10.2337/cd23-0093
-, K. Z., -, R. G., & Tiwari, A. (2024) · International Journal For Multidisciplinary Research · doi:10.36948/ijfmr.2024.v06i01.11140
Curovic, V. R., Persson, F., Jongs, N., et al. (2024) · Diabetes Care · doi:10.2337/dci23-0046
Evolution of insulin therapy in the light of innovative technologies of the 21st century
Demidova, T. Y., & Titova, V. V. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-439
Podocalyxin Urine sebagai Biomarker Prediktor Nefropati Diabetik
Orno, T. G., & Pelu, J. E. (2023) · Health Information Jurnal Penelitian · doi:10.36990/hijp.v15i2.859 · Cited by 2
“Nefropati diabetik (ND) yang disebabkan oleh diabetes melitus merupakan salah satu penyebab utama gagal ginjal stadium akhir di seluruh dunia (Davies et al., 2022).”
BackgroundHeald, A. H., & Krentz, A. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00017-6
Delphi, B. (2023) · The Journal of AMD · doi:10.36171/jamd23.26.4.3
Rivas, C., García, A. K. Z., & Medina, D. (2024) · Ciencia Latina Revista Científica Multidisciplinar · doi:10.37811/cl_rcm.v8i1.9542
Adam, J., Harada, M., Covic, M., Brandmaier, S., Muschet, C., Huang, J., Han, S., Ge, J., Rommel, M., Rotter, M., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-3931333/v1
Belhadj, M., Malek, R., Mallem, N., Mohammedi, A. I., & Serouti, A. (2024) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.01.010
Mishriky, B. M., Cummings, D. M., Fu, Y., Halladay, J. R., Jones, S., Boan, A. D., Jones, S. B., Patil, S. P., Powell, J. R., Adams, A. D., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15499
“9 Given these circumstances, our study aimed to assess the risk of hospitalizations for heart failure among Black and White individuals with type 2 diabetes following the initial prescription of empa-gliflozin, utilizing real-world data obtained from four academic centres.”
BackgroundUPDATED MEDICINES FOR DIABETICS
al-nefaie, M. D., alotaibi, R. H., alotaibi, S. M., Alnafeiai, N. A., Alotaibi, M. A., Alotaibi, M. T., & Alamri, S. A. (2022) · doi:10.53555/jptcp.v29i03.4532
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Disorders: What a Clinician Needs to Know
Kesavadev, J., KOVIL, R. R., Basu, D., Chaudhuri, S. R., & Bhartia, M. (2022) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_2_23
Association of adiponectin with thyroid dysfunction in diabetes mellitus type II
Abd-Alhussain, S. Q., & Sallman, O. S. (2024) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2024.26.2.0066
Hosoki, M., Hori, T., Kaneko, Y., Mori, K., Yasui, S., Tsuji, S., Yamagami, H., Kawata, S., Hara, T., Masuda, S., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051283
Infeções do trato genito-urinário e inibidores SGLT2: estudo caso-controlo numa USF
de Orta, U. G., Lopes, N., Baptista, S., & Teixeira, A. (2024) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v40i1.13850
Negara, A. A. G. A. P., Antari, N. K. A., & Nugraha, M. H. S. (2024) · Journal Of Medicine & Health · doi:10.28932/jmh.v6i1.7850 · Cited by 1
Hoog, M. M., Maldonado, J. M., Dixon, R. W., Halpern, R., Buysman, E. K., Gremel, G. W., Huang, A., & Кониг, М. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01542-5
Yalçın, N., İlhan, A. H., & Alcı, A. (2024) · Kastamonu Medical Journal · doi:10.51271/kmj-0133
Nutrition counsellors’ recommended eating patterns for individuals with type 2 diabetes in the USA
KHOSROVANEH, K. L., Hisamatsu, R., Reiss, J., RAU, J., Oshman, L. D., Diez, H. L., Lee, J. M., Aikens, J. E., Richardson, C. R., & Hafez, D. (2024) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2023-000845 · Cited by 1
Düğer, H., & Uçan, B. (2024) · Anatolian Current Medical Journal · doi:10.38053/acmj.1415215
2) Diabetes Care for Prevention of Cardiovascular Disease
Ueki, K. (2023) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.112.338
Renda, S., & Freeman, J. S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2328511 · Cited by 2
“In general, guidelines recommend that insulin should be added to existing antihyperglycemic therapy when glycemic targets are not met [7,41,49–52].”
BackgroundMontero, A. R., Nassar, C. M., Ahmed, S., & Magee, M. F. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003788 · Cited by 2
PERAWATAN LUKA DIABETIK DI RUMAH PADA PASIEN DIABETES MELLITUS YANG PERNAH DIRAWAT DI RUMAH SAKIT
Hidayah, N., & Abidah, R. S. (2024) · Hospital Majapahit (JURNAL ILMIAH KESEHATAN POLITEKNIK KESEHATAN MAJAPAHIT MOJOKERTO) · doi:10.55316/hm.v16i1.1025 · Cited by 1
Tichler, A., Hertroijs, D. F. L., van Mastrigt, G. A. P. G., et al. (2024) · medRxiv · doi:10.1101/2024.03.10.24304052
Lehmann, R., & Marx, N. (2024) · Springer-Lehrbuch · doi:10.1007/978-3-662-67718-6_6
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01169-x
Guðmundsdóttir, I. Ó., & Sigurðardóttir, Á. K. (2024) · Tímarit hjúkrunarfræðinga · doi:10.33112/th.100.1.4
Pavlíková, B., Breburdova, M., Krčma, M., Kříž, M., Kasparek, J., & Rušavý, Z. (2024) · Life · doi:10.3390/life14050568 · Cited by 1
“…for the Study of Diabetes (ADA/EASD) guidelines, applied also in our country (Czech Republic), in the event of BBI failure, it is appropriate to consider de-escalation of therapy, ideally using GLP-1RA or sodium-glucose contransporter-2 inhibitor (SGLT2i) for their additional benefits [12].”
BackgroundMerker, L., Ebert, T., Schleicher, E. D., Guthoff, M., & Isermann, B. (2024) · Die Diabetologie · doi:10.1007/s11428-024-01186-w
Soetedjo, N. N. M., Permana, H., Hariyanto, T. I., Tendean, M., Kusumawati, M., Ritonga, E., Yanto, T. A., & Suastika, K. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111630
Pitter, V., Lockwood, K. G., & Graham, S. A. (2024) · American Journal of Health Education · doi:10.1080/19325037.2024.2338059
“The ADA emphasizes five Ss: Sweating, strengthening, sleeping, stepping, and sitting (Davies et al., 2022).”
Cetoacidose metabólica: condições clínicas e abordagens terapêuticas
Frazão, L. F. N., de Oliveira, J. M. G., Pereira, M. M., Ramos, J. L. B., dos Santos, D. R. L., Neto, O. B. D. O., Matos, J. P. A., Santos, T. G. D., dos Santos, M. M., dos Santos, G. D., et al. (2024) · Brazilian Journal of Implantology and Health Sciences · doi:10.36557/2674-8169.2024v6n5p1035-1043
Gliflozins - what's new in practise
Škrha, J. (2024) · Medicína pro praxi · doi:10.36290/med.2024.012
Safety and Efficacy of Intermittent Fasting in Type II Diabetes Mellitus Patients on Insulin Therapy
P, S. S. E. (2023) · International Journal of Science and Research (IJSR) · doi:10.21275/sr23212154545
Joint interprofessional education of pharmacy and dietetics undergraduates - a scoping review
Rudzińska, A., Guzy, P., Skowron, A., Gąsowski, J., & Piotrowicz, K. (2024) · BMC Medical Education · doi:10.1186/s12909-024-05411-4 · Cited by 1
“This approach of combining pharmacological and dietary interventions is reflected in the clinical guidelines for diabetes [13–15], hypertension [16], dyslipidaemia [17, 18], chronic kidney disease [19, 20] or exocrine pancreatic insufficiency [21, 22].”
BackgroundAhmed, Y. H., ElBadawi, H., Sultan, I. E., Mohammed, R. A., Aljedaani, H., Abozeid, H. E., & Badawy, M. I. (2024) · Cureus · doi:10.7759/cureus.60979
“Various health authorities [5,6] recommend shifting the diabetes care approach from conventional physician-led care (PLC) to the multidisciplinary health care (MHC) model.”
BackgroundEffects of Dietary Interventions on Type 2 Diabetes Management in Zambia
Musonda, K. (2024) · Global Journal of Health Sciences · doi:10.47604/gjhs.2571
Effect of Cryolipolysis on Insulin Resistance in Type 2 Diabetic Females with Abdominal Obesity
Eid, N., Ghallab, M. A., Sayed, A., Saber, M., & Abdelwahab, M. (2024) · NILES Journal forGeriatric and Gerontology/NILES Journal for Geriatric and Gerontology · doi:10.21608/niles.2024.287055.1088
Inaba, S., Shirai, T., Sanada, M., Miyashita, H., Inoue, G., Nagahisa, T., Wakana, N., Homma, K., Fukuyama, N., & Yamada, S. (2024) · Nutrients · doi:10.3390/nu16111658 · Cited by 1
“In the present study, we focused on a low-carbohydrate diet, which does not restrict protein, fat, or energy, and a therapeutic diet for diabetes mellitus recommended by the EASD and ADA [8].”
BackgroundPrehabilitation in pancreatic surgery: Impact of patient-related modifiable risk factors
Wijma, A. G. (2024) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.1003144373
Nisa, F., Sudirman, S., Walin, W., et al. (2024) · Malahayati International Journal of Nursing and Health Science · doi:10.33024/minh.v7i2.241
Vanderlei, L. A., Guedes, E. M., Oliveira, L. M. D. S., de Vasconcelos, I. J., do Monte, N. L., de Oliveira, L. P., dos Santos, L. B. F., Furtado, L. T. L., Filho, W. L. S., de Oliveira, J. S., et al. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv7n3-236
Vázquez, R., Paredes, A. P. E., Hernández, K. G. C., Pérez, E. G., Batún-Cutz, J. L., Laviada, D. C., & Perera, E. A. (2024) · Research Society and Development · doi:10.33448/rsd-v13i5.45813
Efectos farmacológicos sobre el sistema cardiovascular de los agonistas GLP-1
Rengel-Hinojosa, L. G., & Rojas-Delgado, C. D. (2024) · MQRInvestigar · doi:10.56048/mqr20225.8.2.2024.3591-3608
Zhang, Y., Yin, X., Liu, T., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4428584/v1
Tariq, F., Moazzam, S. H., Youman, E., & Mushtaq, S. (2024) · BioScientific Review · doi:10.32350/bsr.61.04
Medikamentöse Adipositastherapie bei Typ-2-Diabetes
Kantowski, T., Wiesch, C. S. Z., Aberle, J., & Lautenbach, A. (2024) · CME · doi:10.1007/s11298-024-3862-3
Kemp, B. J., Thompson, D. R., COATES, V. E., Bond, S., Ski, C. F., Monaghan, M., & McGuigan, K. (2024) · Health Policy · doi:10.1016/j.healthpol.2024.105116
Ribas-Seguí, D., Forcadell-Peris, M. J., Vila-Córcoles, Á., de Diego‐Cabanes, C., Gondar, O. O., Luján, F. M., & Satué-Gracia, E. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4506982/v1
Pallarés‐Carratalá, V., Ruiz‐García, A., Serrano-Cumplido, A., Segura‐Fragoso, A., Fernández-Pascual, V., Sánchez-Sánchez, B., Cervera-Pérez, M. I., Alonso-Moreno, F. J., Arranz-Martínez, E., Barquilla-García, A., et al. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.arteri.2024.05.001 · Cited by 1
Mohammed, R. S., Sa’idu, G., Salihu, L., & Aliyu, A. O. (2024) · Journal of applied science and environmental management · doi:10.4314/jasem.v28i6.4
Ghosh, S. K., WANGNOO, S. K., Chittawar, S., Damodharan, S., Kadam, Y., Kalra, P., Kumar, K. P. S., Periyandavar, I., Sharma, S. K., & Zargar, A. H. (2024) · Journal of Endocrinology and Metabolism · doi:10.14740/jem946 · Cited by 1
Hadi, H. H., & Al-Ziaydi, A. G. (2024) · Medical Science Journal for Advance Research · doi:10.46966/msjar.v5i2.199
Empowering communities: Education for hypertension and diabetes prevention
Wisnuwardani, R. W., Rachmawati, A., Dzikri, A., et al. (2024) · Abdimas Jurnal Pengabdian Masyarakat Universitas Merdeka Malang · doi:10.26905/abdimas.v9i2.12552
“These recommendations place greater emphasis on addressing social determinants of health, improving the healthcare system, and promoting physical activity, including sleep (Davies et al., 2022).”
BackgroundBarrett, A., Boye, K. S., García‐Pérez, L., Giorgino, F., Guerci, B., Füchtenbusch, M., Yu, M., Sapin, H., Dib, A., Heitmann, E., et al. (2024) · Journal of Medical Economics · doi:10.1080/13696998.2024.2367919
Hauner, H. (2024) · Springer eBooks · doi:10.1007/978-3-662-58895-6_18
Bat‐Erdene, B., He, M. Y., Dong, J., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4900470
Modern insulin treatment for type 2 diabetes
Grønlund, E., Lund, L., Vilsbøll, T., & Hædersdal, S. (2024) · Ugeskrift for Læger · doi:10.61409/v03240172
Kopp, L. H. P., Søgaard-Hansen, C. M., Zachhau, K. M., Bastkjær, R. M., Andersen, B. V., Budtz–Jørgensen, E., Byrne, D. V., Chaaban, N., Holst, J. J., Klindt, T., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-084686
Bexagliflozin in type 2 diabetes: a profile of its use
France, N. L., & Shirley, M. (2024) · Drugs & Therapy Perspectives · doi:10.1007/s40267-024-01098-1
“A HbA 1c of 7% is considered to be a reasonable target for most people with T2DM [2].”
InfluentialHoldt‐Caspersen, N. S., Dethlefsen, C., Hejlesen, O. K., et al. (2024) · Studies in health technology and informatics · doi:10.3233/shti240791
Alves, A. C. D., Correia, E. D. C., Cunha, L. A., & de Mattos, M. P. (2024) · Brazilian Journal of Health Review · doi:10.34119/bjhrv8n4-320 · Cited by 1
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protectionPreprint
Jansz, T. T., Young, K., Hopkins, R., et al. (2024) · medRxiv · doi:10.1101/2024.09.01.24312905
Médicaments du diabète de type 2 : quelle attitude après la nouvelle recommandation de la HAS ?
SCIENTIFIQUE, C. (2024) · EXERCER · doi:10.56746/exercer.2024.205.314
Stupalkowska, W., & Tavakkoli, A. (2024) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2024.09.014
Delbaere, J., Deboever, E., Vaes, B., Nobels, F. R. E., Mamouris, P., & Goderis, G. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.09.003 · Cited by 1
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.